On the stock market since 2021, it operates in the world of health and science. It has 4 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 49% below its peak. The market has trimmed its expectations for the company.
There is $7.5M in the vault; even if every debt were paid off, $7.5M would remain.
A loss of $4.6M against $0 in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.30. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, HITC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HITC is a high-risk stock — not yet profitable, and its future rides on its product catching on.